Literature DB >> 23682974

White-coat hypertension.

Catherine A Martin1, Barry P McGrath.   

Abstract

1. Numerous studies have examined whether white-coat hypertension (WCHT) is associated with increased cardiovascular risk, but with definitions of WCHT that were not sufficiently robust, results have been inconsistent. The aim of the present review was to standardize the evidence by only including studies that used a definition of WCHT consistent with international guidelines. 2. Published studies were reviewed for data on vascular dysfunction, target organ damage, risk of future sustained hypertension and cardiovascular events. 3. White-coat hypertension has a population prevalence of approximately 15% and is associated with non-smoking and slightly elevated clinic blood pressure. Compared with normotensives, subjects with WCHT are at increased cardiovascular risk due to a higher prevalence of glucose dysregulation, increased left ventricular mass index and increased risk of future diabetes and hypertension. 4. In conclusion, management of a patient with WCHT should focus on cardiovascular risk factors, particularly glucose intolerance, not blood pressure alone.
© 2013 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cardiovascular risk; glucose intolerance; isolated clinic hypertension; white-coat hypertension

Mesh:

Substances:

Year:  2014        PMID: 23682974     DOI: 10.1111/1440-1681.12114

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  16 in total

1.  Is white-coat hypertension benign?

Authors:  David B Tsai
Journal:  Can Fam Physician       Date:  2016-04       Impact factor: 3.275

Review 2.  Closer look at white-coat hypertension.

Authors:  Nurver Turfaner Sipahioglu; Fikret Sipahioglu
Journal:  World J Methodol       Date:  2014-09-26

3.  A combined measure of vascular risk for white matter lesions.

Authors:  Amber Watts; Robyn A Honea; Sandra A Billinger; Kathleen T Rhyner; Lewis Hutfles; Eric D Vidoni; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

4.  Racial disparities in hypertension management among multiple sclerosis patients.

Authors:  Devon S Conway; Farren Bs Briggs; Ellen M Mowry; Kathryn C Fitzgerald; Carrie M Hersh
Journal:  Mult Scler Relat Disord       Date:  2022-06-15       Impact factor: 4.808

5.  Early intervention for perioperative hypertension in cataract surgery.

Authors:  Takashi Ono; Takuya Iwasaki; Kana Kawahara; Yuko Agune; Yosai Mori; Ryohei Nejima; Makoto Aihara; Kazunori Miyata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-27       Impact factor: 3.535

6.  Outcomes from a community-based hypertension educational programme: the West of Ireland Hypertension study.

Authors:  M Darrat; A Houlihan; I Gibson; M Rabbitt; G Flaherty; F Sharif
Journal:  Ir J Med Sci       Date:  2017-11-06       Impact factor: 1.568

Review 7.  Home monitoring of blood pressure.

Authors:  Barry P McGrath
Journal:  Aust Prescr       Date:  2015-02-02

8.  Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Mahboob Rahman; Xue Wang; Joshua D Bundy; Jeanne Charleston; Debbie Cohen; Jordana Cohen; Paul E Drawz; Lama Ghazi; Edward Horowitz; James P Lash; Sarah Schrauben; Matthew R Weir; Dawei Xie; Raymond R Townsend
Journal:  J Am Soc Nephrol       Date:  2020-09-24       Impact factor: 10.121

9.  Improved glucose homeostasis in male obese Zucker rats coincides with enhanced baroreflexes and activation of the nucleus tractus solitarius.

Authors:  Parul Chaudhary; Ann M Schreihofer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-09-26       Impact factor: 3.619

10.  White-coat and masked hypertension diagnoses in chronic kidney disease patients.

Authors:  Henrique Pereira; Alessandra Bonilha; Pasqual Barretti; Roberto Silva; Vanessa Burgugi; Vanessa Dos Santos; Luis Cuadrado
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.